Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
Filed with ASX · · 5 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- PAR Expanded Access IND Cleared by US FDA
- Appendix 4E and 2019 Annual Report
- PARs drug reduces cartilage degradation in subjects with OA
- Paradigm files first IND with US FDA
- Appendix 4C - quarterly
Later from Paradigm Biopharmaceuticals
- Paradigm provides regulatory filing update
- Paradigm AGM Presentation
- Paradigm End of Calendar Year Update
- Cleansing Notice and Appendix 3B
- Paradigm presents MPS VI poster at WORLD Symposium
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals